Conformis Inc
F:308
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (12.9), the stock would be worth €-2.21 (283% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -7.1 | €1.21 |
0%
|
| Industry Average | 12.9 | €-2.21 |
-283%
|
| Country Average | 14.4 | €-2.46 |
-303%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
C
|
Conformis Inc
F:308
|
225.2m EUR | -7.1 | -6.4 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
168.1B USD | 14.6 | 26.8 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
166.6B USD | 44.2 | 58.3 | |
| US |
|
Stryker Corp
NYSE:SYK
|
131.3B USD | 20.6 | 40.5 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
110.6B USD | 13.3 | 24 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
95.3B USD | 19.5 | 32.9 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
43.9B EUR | 11.6 | 20.8 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47B USD | 23.9 | 43.8 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
47B USD | 31.3 | 44.3 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
45.1B USD | 10.1 | 25.7 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
34B USD | 11.7 | 16.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
Conformis Inc
Glance View
ConforMIS, Inc. is a medical technology company, which engages in the development, manufacture, and sale of joint replacement implants. The company is headquartered in Billerica, Massachusetts and currently employs 310 full-time employees. The company went IPO on 2015-07-01. The firm is engaged in the development, manufacturing, and sales of patient-specific products and instrumentation that are individually sized and shaped to fit each patient's unique knee and hip anatomy. The Company’s products include iUni, iDuo, iTotal CR, iTotal PS, iTotal Identity, Identity Imprint and Conformis Cordera hip system. The Company’s iFit Image-to-Implant technology platform includes iFit Design, iFit Printing and iFit Just-in-Time Delivery. Its Identity Imprint knee system provides a data-informed knee implant system that provides a level of personalization through its patient-specific instruments (PSI) and proprietary algorithms for pre-surgical planning. Its Image-to-Implant Platinum Services program offering services in United States. The firm offers a line of the sterile, personalized knee and hip implants and single-use instruments delivered to hospitals.
